Autophosphorylation of point mutants of ALK

Stable Identifier
R-HSA-9700186
Type
Reaction
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Oncogenic point mutations in ALK promote ligand-independent transautophosphorylation, leading to constitutive downstream signaling though pathways such as the MAP kinase, PI3K-AKT, PLC gamma and STAT3 cascades (Chen et al, 2008; Mosse et al, 2008; George et al, 2008; Wang et al, 2011; Ceccon et al, 2013; Ceccon et al, 2015; reviewed in Hallberg and Palmer, 2013; Della Corte et al, 2018).

Literature References
PubMed ID Title Journal Year
18724359 Identification of ALK as a major familial neuroblastoma predisposition gene

Hakonarson, H, Kim, C, Speleman, F, Laureys, G, Mossé, YP, Hou, C, Schork, NJ, Maris, JM, Tonini, GP, Devoto, M, Attiyeh, EF, Rappaport, E, Laudenslager, M, Cole, KA, Wood, A, Lynch, JE, Sennett, R, Laquaglia, MJ, Longo, L, Torkamani, A, Perri, P, Brodeur, GM

Nature 2008
29455642 Role and targeting of anaplastic lymphoma kinase in cancer

Troiani, T, Viscardi, G, Morgillo, F, Fasano, M, Martinelli, E, Ciardiello, F, Della Corte, CM, Di Liello, R

Mol. Cancer 2018
18923525 Activating mutations in ALK provide a therapeutic target in neuroblastoma

Zozulya, S, George, RE, Gilliland, DG, Morris, SW, Luther, W, London, WB, Hanna, M, Meyerson, M, McGrady, P, Sanda, T, Gregor, VE, Look, AT, Zhang, J, Fröhling, S, Ahn, Y, Diller, L, Webb, TR, Zhou, W, Greulich, H, Gray, NS, Xue, L

Nature 2008
23239810 Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors

Ceccon, M, Mologni, L, Scapozza, L, Bisson, W, Gambacorti-Passerini, C

Mol. Cancer Res. 2013
24060861 Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

Palmer, RH, Hallberg, B

Nat. Rev. Cancer 2013
21847362 Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer

Lin, SC, Tu, PH, Wang, YW, Lin, KT, Jou, YS, Ko, JY

Neoplasia 2011
25421750 Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma

Piazza, R, Ceccon, M, Giudici, G, Mologni, L, Fontana, D, Gambacorti-Passerini, C, Pirola, A

Mol. Cancer Res. 2015
18923524 Oncogenic mutations of ALK kinase in neuroblastoma

Ohira, M, Kikuchi, A, Soda, M, Kato, M, Choi, YL, Nakagawara, A, Hayashi, Y, Wang, L, Ogawa, S, Chen, Y, Sanada, M, Takita, J, Mano, H, Igarashi, T

Nature 2008
Participants
Participates
Catalyst Activity

protein tyrosine kinase activity of ALK point mutant dimers [plasma membrane]

Normal reaction
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!